

REFERENCE NO.

97

In re application of: Singh, Nikhilesh, et al.
Application No.: 10/763,641
Filing Date: January 22, 2004
Attorney Docket No.: 022205-000110US

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number
WO 01/39836 A1

(51) International Patent Classification⁷: **A61P 25/06, A61K 31/48, 31/42, 31/4196, 31/4045, 31/138, 9/19**

(21) International Application Number: **PCT/IN00/00078**

(22) International Filing Date: **25 August 2000 (25.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
1160/MAS/99 1 December 1999 (01.12.1999) IN

(71) Applicant (for all designated States except US): **NATCO PHARMA LIMITED [IN/IN]**; Natco House, Road No. 2, Banjara Hills, Hyderabad 500 033 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VENKATESWARA RAO, Pavuluri [IN/IN]**; Manager R & D (F), Natco Pharma Limited, Natco House, Road No. 2, Banjara Hills, Hyderabad 500 033 (IN). **KHADGAPATHI, Podili [IN/IN]**; Director- Technical, Natco Pharma Limited, Natco House, Road No. 2, Banjara Hills, Hyderabad 500 033 (IN).


(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/39836 A1

(54) Title: **A RAPID ACTING FREEZE DRIED ORAL PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINE**

(57) Abstract: The present invention relates to a novel freeze - dried pharmaceutical composition useful for the treatment of migraine and associated symptoms at a reduced total dose of active substance than required for oral administration in the form of a tablet containing a porous matrix net work of a water soluble or water dispersible carrier material, a pharmaceutically active substance(s); organoleptic additives such as sweetening agents, flavouring agents, coloring agents; pharmaceutically acceptable preservatives; solubilising agents; surfaceactive agents and/or buffering agents. The pharmaceutical composition optionally may contain other additives such as permeation enhancers, chelating salts and stabilising agents. The present invention also relates to a process for preparation of the above said composition and its use.

AN RAPID ACTING FREEZE DRIED ORAL PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINE

5 This invention relates to an improved fast acting oral pharmaceutical composition. The invention particularly relates to an improved fast-acting, freeze-dried pharmaceutical composition containing an orally active pharmaceutical substance intended for treating migraine and associated symptoms. The invention also relates to a process for preparing such a 10 composition. The composition is intended for rapid systemic absorption of the active substance incorporated in the composition through oral mucosa, thereby eliminating the need for parenteral administration of the medicament for crisis management and is suitable for patients who have difficulty in swallowing solid dosage forms and/or are non cooperative in swallowing medication.

15 In the recent times numerous advances have taken place in the field of pharmacology and pharmaceutics with respect to the administration of drugs to treat various conditions. Despite the tremendous advancements in the field, however, drugs continue to be administered using substantially the same 20 techniques that have been used for many decades. The vast majority of pharmaceutical agents continue to be administered either orally or by injection. Nevertheless, it is frequently found in the art that neither of these administration routes is effective in all cases, and both administration routes suffer from several disadvantages.

25 Oral administration is probably the most prevalent method of administering pharmacological medicaments. The medicament is generally incorporated into a tablet, capsule, or a liquid base, and then swallowed. The oral administration modality is often preferred because of its convenience. In addition, oral administration is generally non-threatening, painless, and simple to accomplish 30 for most patients.

35 Nevertheless, oral administration of drugs suffers from several disadvantages. One disadvantage is that pediatric and geriatric patients frequently have difficulty swallowing pills and other solid dosage-forms, and such patients often refuse to cooperate in swallowing a liquid medication. In addition, for many medicaments, the act of swallowing the medicament often requires fluids that increase gastric volume and the likelihood of nausea and vomiting. This occurs more often in migraine patients.

40 A further problem with oral administration is that the rate of absorption of the drug substance into the bloodstream after swallowing varies from patient to

5 patient. The absorption of the drug substance is dependent upon the movement of the drug substance from the stomach to the small and large intestines and the effects of secretions from these organs and on the resulting pH within the stomach and intestines. Anxiety and stress can dramatically reduce these movements and secretions, prevent or reduce the final effects of the drug substance, and delay onset of the drug's effects.

10 Most significant is the fact that there is normally a substantial delay between the time of oral administration and the time that the therapeutic effect of the drug begins. As mentioned above, the drug must pass through the gastrointestinal system in order to enter the bloodstream; which typically takes forty-five minutes or longer. As mentioned above, anxiety and stress often increase this 15 delay. For many applications, such as pre-medication before surgery or where immediate relief from pain or a serious medical condition or immediate effectiveness of the drug is required, this delay is unacceptable.

20 An additional disadvantage of oral administration is that many drugs almost immediately experience metabolism or inactivation. The veins from the stomach and the small and large intestines pass directly through the liver. Thus, 25 drugs entering the bloodstream must first pass through the liver before distribution into the general blood circulation. More than sixty percent of most drugs (and essentially one hundred percent of certain drugs) are removed from the patient's bloodstream during this "first pass" through the liver. The result is that oral administration is either impractical for many drugs, particularly many central nervous system and many cardiovascular-acting drugs that are used for rapid onset in critical care situations, as a pre-medication prior to surgery or for the induction of anesthesia, or requires very high doses when compared to the 30 parenteral route of administration, ranging from 2.0 to 5.0 fold increase in the total dose administered in a day.

35 Further, additional stress is placed on the liver as it removes the excess drug occurring over an extended period of time. The liver may become overloaded with the drug's metabolite, which then must be excreted. As a result, there is an increased risk of hepatic or renal disorders.

40 Parenteral administration probably is used most, after the oral route for administering medicaments. However parenteral administration has many drawbacks. Parenteral administration is generally threatening, painful, and cumbersome to accomplish for most patients. In addition, the cost of therapy is more when administration is effected by the parenteral route.

Some investigators have suggested that it may be possible to administer medication through the buccal mucosa of the cheek pouch or by sublingual administration. Refer U.S. Pat. No. 4,671,953 entitled "METHODS AND COMPOSITIONS FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS". Such administration through the mucosal tissues of the mouth, pharynx, and esophagus of therapeutic drugs possesses a distinct usefulness. Administration of drugs by this route does not expose the drug to the gastric and intestinal digestive juices. In addition, the drugs largely bypass the liver on the first pass through the body, avoiding additional metabolism and/or inactivation of the drug. Consequently the total dose of the drug required for eliciting the desired therapeutic response is considerably reduced in some instances.

15 Rapid dissolving or disintegrating pharmaceutical dosage forms are available for human patients who have difficulty in swallowing conventional dosage forms such as tablets or capsules and for the sublingual and buccal administration of drug. Most of these dosage forms are prepared either by compression or molding.

20 Compressed tablets are prepared after mixing the active ingredient with suitable excipients, into tablets, which disintegrate in 1 to 3 minutes into granules or fine particles when suspended in water. Moreover such dispersion in water invariably has to be swallowed and the drug has to dissolve in gastrointestinal fluids before being absorbed systemically.

25 Molded tablets are prepared by blending excipients with the drug, mixing with a solvent to make a workable mass, filling into the mold plate with sufficient pressure, ejecting the tablet in wet condition by placing on top of a plate which has projecting pegs and drying. As tablets dry, the solvent migrates to the surface and may carry the active ingredient or other soluble components to the tablet surface. This can produce a non-homogenous distribution of the drug throughout the tablet.

30 While administration of certain drugs through the oral mucosal tissues has shown promise, development of a fully acceptable method for producing a medication in a desirable form and administering the medication has been elusive for long.

35 Many of the disadvantages of rapidly disintegrating compressed and molded tablets mentioned above can be overcome by freeze-dried tablets. Freeze-dried or lyophilised dosage forms are generally known to dissolve rapidly or disintegrate when they come in contact with water or any aqueous fluids. These dosage forms include of an open matrix network of water - soluble or water

dosage forms include of an open matrix network of water – soluble or water dispersible carrier material, which is impregnated with a unit dose of the pharmaceutical active agent. These dosage forms are prepared by first adding the pharmaceutical active to a solution comprising the carrier material and a suitable solvent, typically water. The resulting composition is then subjected to a freeze-drying procedure where by the solvent sublimes under high vacuum.

5 10 By the term “Rapid disintegrating” it is meant that the tablet disintegrates in mouth within 30 seconds, preferably the tablet disintegrates (dissolves or disperses) within 10 seconds or less.

15 20 25 By the term “Open matrix network” it is meant a network of water-soluble or water dispersible carrier material having interstices dispersed throughout. The open matrix network of carrier material is of generally low density. The density of the tablet may be affected by the amount of substance incorporated into the tablet. The open matrix network, which is similar in structure to solid foam, enables a liquid to enter the product through the interstices and permeate through the interior. Permeation by saliva in the mouth exposes the carrier material of both the interior and exterior of the product to the action of saliva where the net work of carrier material is rapidly disintegrated. The open matrix structure is of a porous nature and enhances disintegration of tablet as compared with ordinary tablets, pills and capsules. Rapid disintegration results in rapid release of any drug carried by the matrix.

30 In US Patent US 4 371 516 and GB 2 111 423 (Inventors: Gregory et. al.,) a process and composition of a shaped article carrying chemicals, pharmaceuticals which disintegrate rapidly in water, having an open matrix network of carrier material prepared by sublimation process using a mold was disclosed. Partially hydrolysed gelatin, hydrolysed dextran, dextrin, alginates, polyvinyl alcohol, polyvinylpyrrolidone or acacia were used as carrier materials for administration of pharmaceutical substances.

35 Seager has described a method for preparing rapid- dissolving dosage forms that disintegrate instantaneously releasing the drug which dissolves or disperses in the saliva [Seager, H., J. Pharm. Pharmacol. 1998, 50(4), 375 - 382].

40 In EP 0 636 365 A1 a freeze dried pharmaceutical dosage form containing a porous matrix of a water soluble or water dispersible carrier material which comprises coated pharmaceutical particles was disclosed. The pharmaceutical granules were coated with a blend of water soluble and water insoluble polymers to overcome the bitter taste of the dosage form upon administration allowing the coated particles to be swallowed and is useful for acetaminophen, loperamide,

5 famotidine or aspirin for patients who have difficulty in swallowing conventional tablets or capsules. However the release of drug from coated particles requires some time, which may delay the onset of action.

In US 5 785 989, a composition and methods of manufacture for producing a candy type flavored dissolvable matrix containing medicament capable of absorption through the mucosal tissues of the mouth, pharynx and esophagus 10 useful in administering lipophilic and non lipophilic drugs to which an appliance or holder is attached was disclosed. The solid dosage form is meant for use in the delivery of drug in a pharmacologically effective dose in which the drug being dispersed in a soluble matrix capable of being sucked on while held in the mouth, with attached holder to permit convenient insertion and removal of the 15 drug containing integral mass into and out of the mouth of the patient. The dissolvable matrix optionally contains permeation enhancers and pH buffering agents to increase the absorption of the drug through the mucosal tissue. However this hard to dissolve candy preparation is not suitable for administration to non-cooperative and unconscious patients.

20 In WO 9626714 a process for the preparation of a solid pharmaceutical dosage form comprising a carrier, selegiline hydrochloride as an active ingredient in the form of a fast dispersing dosage form designed to release the active ingredient in the oral cavity has been disclosed.

25 We continued our research work towards developing a composition for the treatment of migraine and associated symptoms considering (i) the requirement of non threatening, painless and simple administration of such drug to the patient especially to pediatric and geriatric patients (ii) the requirement of the 30 onset of action to be rapid meaning that the absorption of the drug is effected through oral mucosa. (iii) requiring only reduced dosage of the drug and that (iv) the medicine can be taken without water.

35 With the information available in the prior art as explained above ,we directed our research work towards developing a pharmaceutical composition useful for the treatment of migraine and associated symptoms which composition can be administered orally and that the active ingredient disintegrates rapidly which in turn results in the rapid release of the drug . To our knowledge such a 40 composition for the treatment of migraine is not hitherto known.

40 Accordingly, the main objective of the present invention is to provide an improved pharmaceutical composition useful for the treatment of migraine and associated symptoms, which can be administered orally.

5 Another objective of the present invention is to provide an improved fast-acting freeze-dried pharmaceutical composition for oral administration, useful for the treatment of migraine and associated symptoms, at reduced total dose of active substance required.

10 Yet another objective of the present invention is to provide an improved pharmaceutical composition for the treatment of migraine and the associated symptoms, which is capable of rapidly disintegrating in the mouth, carrying active substance(s) in the form of free base or its pharmaceutically acceptable salt or ester, thereby allowing the dissolution of the active substance in saliva and transmucosal absorption of the medicament for rapid onset of action.

15 Still another objective of the present invention is to provide a process for manufacture of such an improved pharmaceutical composition.

20 The present invention is based on our finding, as a result of sustained research carried out, that when an anti migraine drug administered orally in the form of a tablet with an open matrix and associated symptoms net work comprising water soluble or water dispersible carrier materials, synergises the drug resulting in the rapid onset of its action i.e., relief from migraine and other associated symptoms. It is further observed that a lower dose of anti migraine drug i.e., 10.0 to 60.0 percent of the orally administered dose, is sufficient to elicit an equal therapeutic 25 response when such a pharmaceutical composition is administered sublingually.

30 Accordingly, the invention provides an improved freeze dried pharmaceutical composition useful for the treatment of migraine and associated symptoms, which comprises one or more pharmaceutically active substances used in the treatment of migraine and associated symptoms of a water soluble and water dispersible carrier material in an open matrix network, as herein defined, with or without co administered active substances and / or other excipients normally employed in such compositions, the resulting composition rapidly disintegrating, as herein defined, in the mouth.

35 Another feature of the invention is to provide a process for the preparation of the improved pharmaceutical composition explained above. The pharmaceutical composition of the present invention is prepared using freeze-drying or lyophilisation process generally known in the art. Such processes are described 40 in U.S. patent Nos. 4,305,502 and 4,371,516 both to Gregory et al, U.S. Patent No.: 4,642,903 to Davies and by Seager [Seager, H., J. Pharm. Pharmcol. 1998, 50(4), 375 - 382].

Accordingly the present invention also provides a process for the preparation of an improved freeze dried pharmaceutical composition useful for the treatment of migraine and associated symptoms, which comprises adding one or more pharmaceutically active substances useful for the treatment of migraine or associated symptoms to a solution / suspension of a water soluble or water dispersible carrier material thereby forming an open matrix network, as herein defined and if necessary, adding other additives normally employed preparing in such compositions transferring the resultant solution / suspension to a mold of the desired shape and size of the final product and freezing the product in a freeze dryer at a temperature in the range of -50 to 10°C and further to drying at a temperature of -40 to 90°C under vacuum of in the range of 1.0×10^{-2} to 7.5×10^{-1} torr.

The additives, which may be employed in the pharmaceutical composition, may be selected from variety of substances. They are exemplified below. The additives may be organoleptic additives such as sweetening agents, flavoring agents, coloring agents; pharmaceutically acceptable preservatives; solubilising agents; surface-active agents and/or buffering agents. The pharmaceutical composition also may contain other additives such as permeation enhancers, chelating salts and stabilising agents.

A wide variety of other active substances that are administered orally also may be incorporated in the pharmaceutical composition of the invention for rapid absorption through oral mucosa. The preferred active substances that are incorporated in the pharmaceutical composition of the invention are those used for the treatment of migraine and associated symptoms such as sumatriptan, zolmitriptan, rizatriptan, ergotamine, propranolol etc.

Typical drugs, which can be administered by this means in combination with the above active substances and useful for the treatment of migraine associated symptoms include drugs such as antihistaminic and antiallergenic agents e.g. chlorpheniramine maleate, diphenhydramine, terphenidine, flunarizine, cetirizine; sympathomimetics e.g. phenylpropanolamine pseudoephedrine; anti emetics e.g. dimenhydrinate, domeperidone, ondansetron, granisetron, prochlorperazine metoclopropamide; analgesic and anti-inflammatory agents e.g. naproxen sodium, paracetamol etc.

The active substance may be present in the form of a base or pharmaceutically acceptable form of its salt or ester having good penetration / absorption through transmucosal layers in the oral cavity. The pharmaceutical composition may carry a combination of active substances intended for the treatment of migraine and the associated symptoms.

5 The active substance may be present in the composition in a therapeutically effective amount that can be readily determined by one skilled in the art. In determining such amounts, the particular compound being administered, the bioavailability characteristics of the pharmaceutical, the dose regime, the age and weight of the patient and other factors must be considered. For example for sumatriptan the dose may range from 5.0 to 50.0mg preferably from 10.0 to 25.0mg.

10 The open net work of carrier materials which may be used in the pharmaceutical composition of the invention may be any water-soluble or water-dispersible inert pharmaceutical excipients capable of forming a rapidly disintegratable open matrix network, preferably a water soluble material since this results in most rapid disintegration of the matrix when the composition is placed in the mouth. Such carrier matrix network may be selected from polyvinyl pyrrolidone, polyvinyl alcohol, partially hydrolysed gelatins, dextrans, alginates, carboxymethyl celluloses pectin's, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, carboxy vinyl polymers such as carbomer 934P and carbomer 974P. Other suitable carrier materials for inclusion in the matrix network include sugars such as dextrose, mannitol, lactose, galactose, cyclodextrins, inorganic salts such as sodium phosphate, sodium chloride and aluminum silicates. Preferred carrier materials include pharmaceutical grade gelatins, pectins (nonhydrolysed and partially hydrolysed); carboxy vinyl polymers; polyvinylpyrrolidone; polyvinyl alcohol; mannitol and mixtures thereof. The amount of such carrier matrix material in the pharmaceutical composition may range from 10.0 to 90.0 percent preferably 30.0 to 70.0 percent by weight on dry basis.

15 20 25 30 35 The pharmaceutical composition also may contain ingredients other than the active substance and carrier matrix forming material. These additional ingredients include buffering agents, organoleptic additives such as sweetening agents, flavoring agents, coloring agents, pharmaceutically acceptable preservatives, solubilising agents and/or surface-active agents. The pharmaceutical composition also may contain additives such as permeation enhancers, chelating salts and stabilising agents.

40 It is desirable to include buffering agents in the composition. Buffering agents provide the ability to place the medication in the mouth in a favorable pH environment for passage across the mucosal tissues of the mouth, pharynx and esophagus. Buffering agents can be used to effect pH change in the salival environment of the mouth in order to favor the existence of a non-ionized form of the active substance, which more rapidly moves through the mucosal tissues. Appropriate pH adjustment can aid in producing a more palatable product with

5 active substances which are either severely acidic (and thus sour) or severely basic (and thus bitter). A buffer system such as citric acid / sodium citrate or citric acid / disodium hydrogen ortho phosphate etc., may be used.

10 The amount of each organoleptic additive when used may range from 0.025 to 5.0 percent by weight on dry basis of the pharmaceutical composition. Preservatives may be added to the pharmaceutical composition as most of the ingredients promote microbial growth in presence of moisture. The preservatives and the concentrations used in the pharmaceutical composition are selected from among those known in art and approved for oral pharmaceutical dosage forms.

15 The composition may also contain surface-active agents such as polysorbate 80, sodium lauryl sulphate and the like to aid in the dispersion of the active substance in the solution / dispersion of the carrier material during manufacturing process and in saliva during administration to the patient. The amount of surface-active agent may range from 0.01 to 2.0% of the pharmaceutical composition on dried basis.

20 The permeability of both lipophilic and non-lipophilic drugs across the oral mucosal membrane may be improved by using suitable permeation enhancers. The permeation enhancers that optionally may be used in the pharmaceutical composition are bile salts such as sodium cholate, sodium glycocholate, sodium 25 glycodeoxycholate, taurodeoxycholate, sodium deoxycholate, etc., sodium dodecyl sulphate, dimethylsulphoxide, sodium lauryl sulphate, salts and other derivatives of saturated and unsaturated fatty acids, bile salt analogs, derivatives of bile salts, surfactants, or such synthetic permeation enhancers as described in U.S. Pat. No. 4, 746, 508.

30 The permeation enhancer concentration within the freeze-dried pharmaceutical composition may be varied depending on the potency of the enhancer and the rate of dissolution of the active substance in saliva. A toxic effect to mucus membrane or irritation sets the upper limit for enhancer concentration.

35 Chelating salts and other stabilising agents known in the art optionally may be employed in the pharmaceutical composition to enhance the stability of the active substance incorporated. Salts of citric acid, edetic acid etc., may be used as chelating salts, the amount of which may range from 0.005 to 2.0 percent by 40 weight of pharmaceutical composition on dry basis. Cyclodextrins, hydroxypropyl methylcellulose and the like may be used as stabilising agents.

The depression in the mould used in the process of making the composition may be significantly larger in which case the final product can be cut into the

desired shape to the desired shape and sizes after the freeze-drying process is completed .

5 The molds may also be coated or lined for easy removal of the freeze-dried pharmaceutical composition. Preferred molds are made from polypropylene, polyvinyl chloride filled with talc and/or simethicone, aluminum with a layer of hydrogenated vegetable oil, silicone / simethicone baked onto the surface of the mold in contact with the solution/suspension. Blisters may also be used which may be made out of polyvinylchloride or polyvinyl dichloride coated polyvinylchloride or aluminum films.

10 15 To facilitate the dissolution / dispersion of the active ingredient in water to form the open matrix net work , a co-solvent such as ethyl alcohol, tert-butyl alcohol and/or solubilising agents such as cyclodextrins, lecithin and non-ionic surface-active agents e.g. sorbitan esters and polysorbates may be used . The amount of such co-solvent when used may range from 2.0 to 25.0 percent, more preferably from 5.0 to 15.0 percent of the total volume of solvent used in the process. The 20 amount of solubilising agent when used ,may range from 0.1 to 5.0 percent, preferably 0.5 to 2.5 percent by weight of pharmaceutical composition on dry basis.

25 Optionally, the active substances are dissolved in water by incorporating a small quantity of acids such as citric acid, sulphuric acid, hydrochloric acid followed by pH adjustment to 4.5 to 6.5 with pharmaceutically acceptable buffering agents such as sodium citrate or disodium hydrogen ortho phosphate.

30 Once the freeze-drying process is complete, the freeze-dried pharmaceutical composition is transferred to a moisture-impervious packaging, such as blister pack. Alternately when the solution / suspension is freeze-dried within preformed blisters, the blisters are sealed with aluminum foil having a suitable sealing layer on the inner side. To remove the tablet from the blister, perforation is provided one side of the blister.

5 The invention is described in detail in the Examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.

EXAMPLE - 1

10 Each tablet contains:

| | |
|-----------------------------------|------------|
| Sumatriptan | 7.50 mg |
| Citric acid anhydrous | 1.68 mg |
| Disodium hydrogen ortho phosphate | 2.42 mg |
| Polyvinyl alcohol | 3.0 % w/w |
| 15 Mannitol | 25.0 % w/w |
| Methyl paraben sodium | 0.1 % w/w |
| Propyl paraben sodium | 0.01%w/w |

20 Sumatriptan is dissolved in purified water with the addition of a few drops of diluted sulphuric acid and added to a solution of polyvinyl alcohol, mannitol and methyl paraben sodium and propyl paraben sodium in water. Citric acid anhydrous and disodium hydrogen ortho phosphate are added in the form of a 0.05M solution to adjust the pH of the solution between 3.0 – 4.0. Purified water is added up to volume. The resultant solution is filtered and 0.30ml of this 25 solution is transferred to a mold having depressions and freeze dried at a temperature of -20 to 40°C and vacuum of 1.0×10^{-2} to 1.0×10^{-1} torr. The freeze-dried tablets are collected into a moisture resistant container.

EXAMPLE - 2

5

Each tablet contains:

| | |
|-----------------------------------|------------|
| Sumatriptan | 15.0 mg |
| Citric acid anhydrous | 1.68 mg |
| Disodium hydrogen ortho phosphate | 2.42 mg |
| 10 Polyvinyl pyrrolidone | 1.0 % w/w |
| Partially hydrolysed gelatin | 1.0 % w/w |
| Mannitol | 75.0 % w/w |
| Methyl paraben sodium | 0.1 % w/w |
| Propyl paraben sodium | 0.01%w/w |
| 15 Pineapple flavour | 0.1 % w/w |

Sumatriptan is dissolved in purified water with the addition of a few drops of diluted sulphuric acid and added to a solution of polyvinyl pyrrolidone, partially hydrolysed gelatin, mannitol, pineapple flavour and methyl paraben sodium and propyl paraben sodium in water. Citric acid anhydrous and disodium hydrogen ortho phosphate are added in the form of a 0.05M solution to adjust the pH of the solution between 3.0 – 4.0. Purified water is added up to volume. The resultant solution is filtered and 0.30ml of this solution is transferred to preformed blisters and freeze dried at a temperature of -20 to 40°C and vacuum of 1.0×10^{-2} to 1.0×10^{-1} torr. The freeze-dried tablets are collected into a moisture resistant container.

EXAMPLE - 3

5

Each tablet contains:

| | | |
|----|-----------------------------------|------------|
| | Sumatriptan Succinate | 14.0 mg |
| | Disodium hydrogen ortho phosphate | 2.42 mg |
| | Gelatin partially hydrolysed | 3.0 % w/w |
| 10 | Mannitol | 50.0 % w/w |
| | Methyl paraben sodium | 0.1 % w/w |
| | Propyl paraben sodium | 0.01%w/w |
| | Pineapple flavour | 0.1 % w/w |
| | Straw berry flavour | 0.05%w/w |

15

Sumatriptan succinate is dissolved in purified water. Disodium hydrogen ortho phosphate is added in the form of a 0.05M solution to adjust the pH of the solution between 4.0 – 5.5. This solution is added to a solution of partially hydrolysed gelatin. Mannitol, strawberry flavour, pineapple flavour and methyl paraben sodium and propyl paraben sodium are dissolved in the solution. Purified water is added up to volume. The resultant solution is filtered and 0.30ml of this solution is transferred to a mold containing depressions and freeze dried at a temperature of -20 to 40°C and vacuum of 1.0×10^{-2} to 1.0×10^{-1} torr. The freeze-dried tablets are collected into a moisture resistant container.

EXAMPLE - 4

5

Each tablet contains:

| | |
|--------------------------------------|------------|
| Sumatriptan succinate | 14.00 mg |
| Ondansetron hydrochloride dihydrate | 5.0 mg |
| Citric acid anhydrous | 1.68 mg |
| 10 Disodium hydrogen ortho phosphate | 2.42 mg |
| Polyvinyl alcohol | 3.0 % w/w |
| Mannitol | 25.0 % w/w |
| Methyl paraben sodium | 0.1 % w/w |
| Propyl paraben sodium | 0.01%w/w |

15

Sumatriptan succinate and ondansetron hydrochloride dihydrate are dissolved in purified water and added to a solution of polyvinyl alcohol, mannitol and methyl paraben sodium and propyl paraben sodium in water. Citric acid anhydrous and disodium hydrogen ortho phosphate are added in the form of a 0.05M solution 20 to adjust the pH of the solution between 3.0 – 4.0. Purified water is added up to volume. The resultant solution is filtered and 0.30ml of this solution is transferred to a mold containing depressions and freeze dried at a temperature of -20 to 40°C and vacuum of 1.0×10^{-2} to 1.0×10^{-1} torr. The freeze-dried tablets are collected into a moisture resistant container.

25

EXAMPLE - 5

5

Each tablet contains:

| | |
|-----------------------------------|------------|
| Zolmitriptan | 7.50 mg |
| Citric acid anhydrous | 1.68 mg |
| Disodium hydrogen ortho phosphate | 2.42 mg |
| 10 Gelatin, partially hydrolysed | 3.0 % w/w |
| Mannitol | 25.0 % w/w |
| Methyl paraben sodium | 0.1 % w/w |
| Propyl paraben sodium | 0.01%w/w |

15 Zolmitriptan is dispersed in purified water. Citric acid anhydrous and disodium hydrogen ortho phosphate are added in the form of a 0.05M solution to adjust the pH of the suspension between 4.0 – 5.5. This suspension is added to a solution of partially hydrolysed gelatin in which mannitol, methyl paraben sodium and propyl paraben sodium are dissolved. Purified water is added up to 20 volume. The resultant dispersion is transferred in 0.30ml quantities to a mold containing depressions and freeze dried at a temperature of -20 to 40°C and vacuum of 1.0×10^{-2} to 1.0×10^{-1} torr. The freeze-dried tablets are collected into a moisture resistant container.

25

30

EXAMPLE - 6

5

Each tablet contains:

Zolmitriptan 7.50 mg

Ondansetron hydrochloride dihydrate 5.0 mg

Citric acid anhydrous 1.68 mg

10 Disodium hydrogen ortho phosphate 2.42 mg

Polyvinyl alcohol 3.0 % w/w

Mannitol 25.0 % w/w

Methyl paraben sodium 0.1 % w/w

Propyl paraben sodium 0.01%w/w

15

Zolmitriptan and ondansetron hydrochloride dihydrate are dispersed in purified water and added to a solution of polyvinyl alcohol, mannitol and methyl paraben sodium and propyl paraben sodium in water. Citric acid anhydrous and disodium hydrogen ortho phosphate are added in the form of a 0.05M solution

20 to adjust the pH of the solution between 3.0 – 4.0. Purified water is added up to volume. The resultant dispersion is transferred in 0.30ml quantities to a mold containing depressions and freeze dried at a temperature of -20 to 40°C and vacuum of 1.0×10^{-2} to 1.0×10^{-1} torr. The freeze-dried tablets are collected into a moisture resistant container.

25

EXAMPLE - 7

5

Each tablet contains:

| | |
|--------------------------|------------|
| Ergotamine tartrate | 1.0 mg |
| Prochlorperazine maleate | 2.5 mg |
| Mannitol | 25.0 % w/w |
| 10 Methyl paraben sodium | 0.1 % w/w |
| Propyl paraben sodium | 0.01 %w/w |
| Gelatin | 1.0 % w/v |

15 Gelatin is dissolved in water and is partially hydrolysed by autoclaving for 2 hours at 121°C and 15 lb pressure. Mannitol, ergotamine tartrate and prochlorperazine maleate are dissolved in 1% w/v gelatin solution (partially hydrolysed) containing methyl paraben sodium and propyl paraben sodium as preservatives. Purified water is added up to volume. The resultant solution is filtered and 0.30ml of this solution is transferred to a mold containing 20 depressions and freeze dried at a temperature of -20 to 40°C and vacuum of 1.0×10^{-2} to 1.0×10^{-1} torr. The freeze-dried tablets are collected into a moisture resistant container.

EXAMPLE - 8

5

Each tablet contains:

| | |
|-----------------------------------|------------|
| Sumatriptan | 10.0mg |
| Citric acid anhydrous | 1.68 mg |
| Disodium hydrogen ortho phosphate | 2.42 mg |
| 10 Carbomer 934P | 0.5 % w/w |
| Mannitol | 25.0 % w/w |
| Methyl paraben sodium | 0.1 % w/w |
| Propyl paraben sodium | 0.01%w/w |

15 Sumatriptan is dispersed in purified water and added to a suspension of carbomer 934P in which mannitol and methyl paraben sodium and propyl paraben sodium were dissolved. Citric acid anhydrous and disodium hydrogen ortho phosphate are added in the form of a 0.05M solution to adjust the pH of the suspension between 4.0 to 5.0. Purified water is added up to volume. The
20 resultant suspension is transferred in 0.30ml quantities to a preformed polyvinyl dichloride coated polyvinyl chloride blister and freeze dried at a temperature of -20 to 40°C and vacuum of 1.0×10^{-2} to 1.0×10^{-1} torr. The freeze-dried tablets are sealed in the blister using aluminum foil.

Advantages of the invention:

- 5 The invention has the advantage of
 - 1) rapid onset of action due to the rapid absorption of the active substance through oral mucosa.
 - 2) reduced dosage of the drugs as absorption through oral mucosa bypasses the first-pass metabolism and over comes possible degradation in the gastrointestinal tract.
 - 10 3) easy to administer to pediatric and geriatric patients.
 - 15 4) medicament can be taken without water.

Although a detailed description of the invention has been provided above, the invention is not limited thereto, and modifications not departing from the spirit and scope of the invention will be apparent to those skilled in the art. The 20 invention is defined by the attached claims.

25

30

35

We Claim:

- 5 1. An improved freeze dried oral pharmaceutical composition useful for the treatment of migraine and associated symptoms, which comprises one or more pharmaceutically active substances used in the treatment of migraine and associated symptoms and a water soluble and water dispersible carrier material in an open matrix network, as herein defined, with or without co administered active substances and / or other excipients normally employed in such oral compositions, the resulting composition rapidly disintegrating, as herein defined, in the mouth.
- 10 2. An improved pharmaceutical composition as claimed in claim 1 wherein active substance(s) useful for the treatment of migraine employed in the composition is/are selected from sumatriptan, zolmitriptan, rizatriptan, ergotamine, propranolol and the like, the active substance(s) being present in the form of its/ their base(s) or pharmaceutically acceptable form of its / their salt(s) or ester(s) and the amount required is equivalent to or higher than the unit dose required for parenteral administration but 2 to 10 times less than the unit dose required for oral administration.
- 15 3. An improved pharmaceutical composition as claimed in claims 1 & 2 wherein the co-administered active substance(s) useful for the treatment of migraine associated symptoms employed in the composition is/are selected from drugs such as antihistaminic and antiallergenic agents e.g. chlorpheniramine maleate, diphenhydramine, terphenidine, flunarizine, cetirizine; sympathomimetics e.g. phenylpropanolamine pseudoephedrine; anti emetics e.g. dimenhydrinate, domeperidone, ondansetron, granisetron, prochlorperazine metoclopropamide; analgesic and anti-inflammatory agents e.g. naproxen sodium, paracetamol and the like and the amount is equivalent to a unit dose required to elicit desired therapeutic response.
- 20 4. An improved pharmaceutical composition as claimed in claims 1 to 3 wherein the carrier material used for forming the open matrix network is selected from polyvinyl pyrrolidone, polyvinyl alcohol, partially hydrolysed gelatins, dextrans, alginates, carboxymethyl celluloses, pectins, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, carboxy vinyl polymers such as carbomer 934P and carbomer 974P; sugars such as dextrose, mannitol, lactose, galactose, cyclodextrins; inorganic salts such as sodium phosphate, sodium chloride and aluminum silicates, the preferred carrier materials include pharmaceutical grade gelatins, pectins (nonhydrolysed and partially hydrolysed); carboxy vinyl polymers; polyvinylpyrrolidone; polyvinyl alcohol; mannitol and mixtures thereof, and the amount of the

carrier material employed ranges from 10.0 to 90.0 percent, preferably from 30.0 to 70.0 percent by weight of the composition on dry basis.

5 5. An improved pharmaceutical composition as claimed in claims 1 to 4 wherein organoleptic additives such as flavoring agents, sweetening agents or colouring agents, buffering agents such as citric acid / sodium citrate or citric acid / disodium hydrogen ortho phosphate and the like, anti-microbial preservatives, are incorporated in the composition.

10 6. An improved pharmaceutical composition as claimed in claims 1 to 5 wherein solubilising agent, for dissolving the active substance, selected from substances such as cyclodextrins, lecithin, surface-active agent such as sorbitan esters, polysorbates, sodium lauryl sulphate and the like is incorporated in the composition and the amount ranges from 0.1 to 5.0 percent, preferably from 0.5 to 2.5 percent of the composition by weight on dry basis.

15 7. An improved pharmaceutical composition as claimed in claims 1 to 6 wherein a penetration enhancer selected from substances like bile salts such as sodium cholate, sodium glycocholate, sodium glycocodeoxycholate, taurodeoxycholate, sodium deoxycholate; surfactants such as sodium dodecyl sulphate, docusate sodium, sodium lauryl sulphate; salts and other derivatives of saturated and unsaturated fatty acids; bile salt analogs; derivatives of bile salts, surfactants, or synthetic permeation enhancers and a stabilizing agent such as salts of citric acid and edetic acid and the like are incorporated in the composition.

20 8. A process for the preparation of an improved freeze dried oral pharmaceutical composition useful for the treatment of migraine and associated symptoms as claimed in claims 1 to 7 which comprises adding one or more pharmaceutically active substances useful for the treatment of migraine or associated symptoms to a solution / suspension of a water soluble or water dispersible carrier material thereby forming the open matrix network, as herein defined and if necessary adding other additives normally employed in preparing such compositions transferring the resultant solution / suspension to a mold of the desired shape and size of the final product and freezing the product in a freeze dryer at a temperature in the range of -50 to 10°C and further drying at a temperature of -40 to 90°C under vacuum of in the range of 1.0×10^{-2} to 7.5×10^{-1} torr.

25

30

35

40

9. An improved freeze dried oral pharmaceutical composition useful for the treatment of migraine and associated symptoms substantially as herein described with reference to the Examples.
10. A process for the preparation of an improved freeze dried oral pharmaceutical composition useful for the treatment of migraine and associated symptoms substantially as herein described with reference to the Examples.

15

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IN 00/00078

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61P25/06 A61K31/48 A61K31/42 A61K31/4196 A61K31/4045
 A61K31/138 A61K9/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| X | US 4 078 065 A (FRANZ JOACHIM) 7 March 1978 (1978-03-07) | 1,2,4-10 |
| Y | column 6, line 33-37; claim 9; example 35 column 1, line 21-23 --- | 1-10 |
| X | US 5 151 264 A (NGUYEN FREDERIQUE ET AL) 29 September 1992 (1992-09-29) | 1,2,4-10 |
| Y | column 4, line 60-68; claims 17,18; examples 5,8 --- | 1-10 |
| X | WO 98 08490 A (AMSELEM SHIMON ;PHARMOS CORP (US)) 5 March 1998 (1998-03-05) | 1,3-10 |
| Y | page 8, paragraph 36 -page 9, line 8; claims 16,17,21 --- | 1-10 |
| X | EP 0 774 253 A (BOUCHARA SA) 21 May 1997 (1997-05-21) | 1-10 |
| Y | claims 1-7; examples 1-3 --- | 1-10 |
| | -/- | |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

11 April 2001

Date of mailing of the international search report

20/04/2001

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/IN 00/00078

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| X | WO 96 15785 A (GLAXO WELLCOME INC ;WINTERBORN IAN KEITH (GB)) 30 May 1996 (1996-05-30) page 4, line 1-27 page 6, line 23; claims 1-6 ----- | 1,3-10 |
| Y | EP 0 255 141 A (GOEDECKE AG) 3 February 1988 (1988-02-03) page 3, line 14-27; claims 1-10 ----- | 1-10 |
| X | GB 2 166 952 A (HANCOCK KENNETH ANTHONY; TURNER JOHN WILLIAM) 21 May 1986 (1986-05-21) page 1, line 80,81; claims 1-9 ----- | 1,3,8-10 |
| Y | | 1-10 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

| | |
|------------------------------|-----------------|
| International Application No | PCT/IN 00/00078 |
|------------------------------|-----------------|

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|--|------------------|-------------------------|------|------------------|
| US 4078065 | A 07-03-1978 | AT 359196 | B | 27-10-1980 |
| | | AT 510975 | A | 15-03-1980 |
| | | AU 507674 | B | 21-02-1980 |
| | | AU 8273675 | A | 06-01-1977 |
| | | BE 831041 | A | 05-01-1976 |
| | | CA 1057196 | A | 26-06-1979 |
| | | CH 615098 | A | 15-01-1980 |
| | | DE 2528257 | A | 22-01-1976 |
| | | ES 439074 | A | 16-05-1977 |
| | | FR 2276833 | A | 30-01-1976 |
| | | GB 1513383 | A | 07-06-1978 |
| | | HK 17281 | A | 08-05-1981 |
| | | HU 172531 | B | 28-09-1978 |
| | | IE 41573 | B | 30-01-1980 |
| | | IL 47623 | A | 31-05-1979 |
| | | JP 51032722 | A | 19-03-1976 |
| | | MY 37281 | A | 31-12-1981 |
| | | NL 7507745 | A | 06-01-1976 |
| | | PH 13763 | A | 18-09-1980 |
| | | SE 436831 | B | 28-01-1985 |
| | | SE 7507413 | A | 05-01-1976 |
| | | ZA 7504303 | A | 23-02-1977 |
| US 5151264 | A 29-09-1992 | FR 2631826 | A | 01-12-1989 |
| | | AT 77741 | T | 15-07-1992 |
| | | DE 68901955 | D | 06-08-1992 |
| | | DE 68901955 | T | 04-02-1993 |
| | | EP 0344040 | A | 29-11-1989 |
| | | ES 2054048 | T | 01-08-1994 |
| | | WO 8911271 | A | 30-11-1989 |
| | | GR 3005670 | T | 07-06-1993 |
| | | JP 2864033 | B | 03-03-1999 |
| | | JP 4500662 | T | 06-02-1992 |
| | | KR 124414 | B | 25-11-1997 |
| WO 9808490 | A 05-03-1998 | US 5891469 | A | 06-04-1999 |
| | | AU 4237397 | A | 19-03-1998 |
| | | EP 1017366 | A | 12-07-2000 |
| EP 0774253 | A 21-05-1997 | FR 2741532 | A | 30-05-1997 |
| WO 9615785 | A 30-05-1996 | AT 193444 | T | 15-06-2000 |
| | | AU 704160 | B | 15-04-1999 |
| | | AU 4173996 | A | 17-06-1996 |
| | | BE 1010250 | A | 07-04-1998 |
| | | BR 9509808 | A | 21-10-1997 |
| | | CA 2205600 | A | 30-05-1996 |
| | | CN 1171741 | A | 28-01-1998 |
| | | CZ 9701549 | A | 15-10-1997 |
| | | DE 69517332 | D | 06-07-2000 |
| | | DE 69517332 | T | 30-11-2000 |
| | | DK 793495 | T | 09-10-2000 |
| | | EP 0793495 | A | 10-09-1997 |
| | | ES 2147309 | T | 01-09-2000 |
| | | FI 972167 | A | 21-05-1997 |
| | | FR 2727016 | A | 24-05-1996 |
| | | GB 2295318 | A, B | 29-05-1996 |
| | | HK 1009591 | A | 20-04-2000 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IN 00/00078

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|--|------------------|-------------------------|-------------|------------------|
| WO 9615785 | A | HU 77886 | A | 28-09-1998 |
| | | IL 116084 | A | 31-01-2000 |
| | | IT RM950762 | A | 22-05-1996 |
| | | JP 3001264 | B | 24-01-2000 |
| | | JP 10508864 | T | 02-09-1998 |
| | | NO 972325 | A | 22-05-1997 |
| | | NZ 296982 | A | 26-06-1998 |
| | | PL 320295 | A | 15-09-1997 |
| | | PT 793495 | T | 31-10-2000 |
| | | SI 793495 | T | 31-10-2000 |
| | | US 5955488 | A | 21-09-1999 |
| | | US 6063802 | A | 16-05-2000 |
| | | ZA 9509821 | A | 31-07-1996 |
| EP 0255141 | A | 03-02-1988 | DE 3626097 | A 11-02-1988 |
| | | | AT 77746 | T 15-07-1992 |
| | | | AU 592463 | B 11-01-1990 |
| | | | AU 7628287 | A 04-02-1988 |
| | | | CA 1285938 | A 09-07-1991 |
| | | | DE 3780095 | A 06-08-1992 |
| | | | ES 2038139 | T 16-07-1993 |
| | | | GR 3005096 | T 24-05-1993 |
| | | | JP 63035522 | A 16-02-1988 |
| | | | PH 24931 | A 26-12-1990 |
| | | | US 4724266 | A 09-02-1988 |
| | | | ZA 8705688 | A 27-04-1988 |
| GB 2166952 | A | 21-05-1986 | US 4704279 | A 03-11-1987 |